Circulating myostatin as a biomarker of muscle mass and strength in individuals with cancer or obesity
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.Myostatin (MSTN) levels correlate positively with muscle mass and strength in individuals with cancer or obesity. This suggests MSTN could serve as a biomarker for muscle health and a screening tool for conditions like cancer cachexia and sarcopenic obesity.
Area Of Science
- Biochemistry
- Physiology
- Oncology
Background
- Cancer cachexia (CC) and sarcopenic obesity (SO) are complex conditions characterized by muscle loss and weakness.
- Myostatin (MSTN), a protein regulating muscle growth, is implicated in these conditions, but its precise role requires further investigation.
Purpose Of The Study
- To investigate the association between myostatin (MSTN) levels and muscle mass/strength in individuals with cancer or obesity.
- To evaluate MSTN's potential as a biomarker for cancer cachexia (CC) and sarcopenic obesity (SO).
Main Methods
- The study involved two cohorts: ACTICA (individuals with and without CC) and MYDIASECRET (individuals with obesity before and after bariatric surgery).
- Muscle mass (SMMI, ASMMI) and handgrip strength (HGS) were measured. Plasma MSTN levels were determined using ELISA.
- Spearman correlation and ROC curve analysis were employed to assess MSTN's association with muscle parameters and its predictive value for CC and SO.
Main Results
- Lower muscle mass, strength, and MSTN levels were observed in individuals with CC compared to controls.
- Muscle mass and strength were positively correlated with MSTN levels in both cohorts.
- ROC analysis identified specific MSTN cutoff levels predictive of CC and SO.
Conclusions
- Myostatin (MSTN) is positively correlated with muscle mass and strength in individuals with cancer or obesity.
- MSTN shows potential as a biomarker for muscle mass and strength.
- MSTN may serve as a valuable screening tool for cancer cachexia and sarcopenic obesity.
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
Related Concept Videos
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Satellite stem cells or myosatellite cells are quiescent stem cells that Alexander Mauro first identified in 1961. These cells are located between the sarcolemma, the plasma membrane of muscle fibers, and the basal lamina, the connective tissue sheath covering it. These mononucleated cells are activated in response to muscle injury, can transform into myoblasts, and may form or repair muscle fibers. Myosatellite cells can provide additional myonuclei for muscle regeneration or return to a...